Cable Car Capital LP Invests $741,000 in MAIA Biotechnology, Inc. $MAIA

Cable Car Capital LP purchased a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 514,583 shares of the company’s stock, valued at approximately $741,000. Cable Car Capital LP owned about 0.85% of MAIA Biotechnology at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. PVG Asset Management Corp purchased a new position in shares of MAIA Biotechnology during the first quarter worth approximately $46,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the second quarter worth approximately $52,000. Corsair Capital Management L.P. bought a new stake in shares of MAIA Biotechnology in the 1st quarter worth approximately $140,000. Finally, Geode Capital Management LLC boosted its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares in the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Stock Up 4.4%

Shares of NYSEAMERICAN:MAIA opened at $1.41 on Wednesday. The stock has a market cap of $85.77 million, a PE ratio of -2.27 and a beta of 0.24. The company’s fifty day moving average is $1.37 and its 200 day moving average is $1.45. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

Insider Buying and Selling at MAIA Biotechnology

In other news, Director Stan Smith bought 75,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was purchased at an average price of $1.34 per share, with a total value of $100,500.00. Following the transaction, the director owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. The trade was a 5.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vlad Vitoc bought 72,700 shares of the stock in a transaction dated Monday, June 1st. The stock was purchased at an average price of $1.39 per share, with a total value of $101,053.00. Following the purchase, the chief executive officer owned 976,121 shares in the company, valued at $1,356,808.19. This trade represents a 8.05% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 161,599 shares of company stock valued at $220,535 over the last 90 days. Company insiders own 19.81% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.